JP2011515462A - 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 - Google Patents

置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 Download PDF

Info

Publication number
JP2011515462A
JP2011515462A JP2011501736A JP2011501736A JP2011515462A JP 2011515462 A JP2011515462 A JP 2011515462A JP 2011501736 A JP2011501736 A JP 2011501736A JP 2011501736 A JP2011501736 A JP 2011501736A JP 2011515462 A JP2011515462 A JP 2011515462A
Authority
JP
Japan
Prior art keywords
difluoromethyl
morpholinyl
triazin
methoxy
chloroacetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2011501736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515462A5 (https=
Inventor
ウイルリアム レウカストレ ゴルドン
ロビン シェプヘルド ペテル
チャウスサデ クライレ
アレクアンデル デンンイ ウイルリアム
アクラトイヤ ガマゲ スワルナラトハ
Original Assignee
アウククランド ウニセルビセス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アウククランド ウニセルビセス リミテッド filed Critical アウククランド ウニセルビセス リミテッド
Publication of JP2011515462A publication Critical patent/JP2011515462A/ja
Publication of JP2011515462A5 publication Critical patent/JP2011515462A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011501736A 2008-03-27 2009-03-26 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 Abandoned JP2011515462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4006408P 2008-03-27 2008-03-27
US61/040,064 2008-03-27
PCT/NZ2009/000038 WO2009120094A2 (en) 2008-03-27 2009-03-26 Substituted pyrimidines and triazines and their use in cancer therapy

Publications (2)

Publication Number Publication Date
JP2011515462A true JP2011515462A (ja) 2011-05-19
JP2011515462A5 JP2011515462A5 (https=) 2012-05-17

Family

ID=40810252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501736A Abandoned JP2011515462A (ja) 2008-03-27 2009-03-26 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用

Country Status (4)

Country Link
US (1) US20110053907A1 (https=)
EP (1) EP2276750A2 (https=)
JP (1) JP2011515462A (https=)
WO (1) WO2009120094A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521983A (ja) * 2009-03-27 2012-09-20 パトフワイ トヘラペウトイクス インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
JP2013525419A (ja) * 2010-04-30 2013-06-20 ユニバーシティ・オブ・バーゼル 抗増殖性障害の処置における使用のためのｐｉ３ｋ阻害剤としてのピペラジノトリアジン
JP2016516702A (ja) * 2013-03-13 2016-06-09 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128088A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Systems and methods for tissue imaging
CA2716940C (en) * 2008-02-29 2016-01-19 The Regents Of The University Of Michigan Systems and methods for imaging changes in tissue
JPWO2010092962A1 (ja) * 2009-02-12 2012-08-16 アステラス製薬株式会社 へテロ環誘導体
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
WO2010110686A1 (en) * 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2013505965A (ja) * 2009-09-29 2013-02-21 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋ（デルタ）選択的阻害剤
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
EP2604601B1 (en) * 2010-08-10 2016-02-24 Astellas Pharma Inc. Hetero ring compound
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
AU2012275114A1 (en) 2011-06-29 2014-01-16 The Regents Of The University Of Michigan Analysis of temporal changes in registered tomographic images
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
AU2012318874A1 (en) * 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors
WO2013078370A1 (en) 2011-11-23 2013-05-30 The Regents Of The University Of Michigan Voxel-based approach for disease detection and evolution
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013166416A1 (en) 2012-05-04 2013-11-07 The Regents Of The University Of Michigan Mean diffusivity measurement corrections for gradient non-linearity
RS56494B1 (sr) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
US10650512B2 (en) 2016-06-14 2020-05-12 The Regents Of The University Of Michigan Systems and methods for topographical characterization of medical image data
EP4086250B1 (en) 2016-07-06 2024-12-11 The Regents Of The University Of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
AU2018316175B2 (en) 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA3116339A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
CN113004246B (zh) * 2021-02-22 2022-02-01 广西医科大学 1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途
US20240217960A1 (en) * 2021-04-09 2024-07-04 Universität Basel Triazine derivative as covalent inhibitors of pi3k
CN117751127A (zh) * 2021-08-20 2024-03-22 南京大美生物制药有限公司 一种五元含氮杂环并杂芳基类衍生物及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1222049B (it) * 1987-07-16 1990-08-31 Ciba Geygi Spa Composti piperidin triazinici utilizzabili come stabilizzanti per polimeri sintetici
US5244948A (en) * 1988-06-30 1993-09-14 Ciba-Geigy Corporation Process for the stabilization of polyolefins
US5306495A (en) * 1988-08-04 1994-04-26 Ciba-Geigy Corporation Compounds containing substituted piperidine groups for use as stabilizers for organic materials
IT1237126B (it) * 1989-11-07 1993-05-18 Ciba Geigy Spa Stabilizzanti polimerici contenenti gruppi amminici impediti e gruppi idrossilamminici
US5258138A (en) * 1990-07-20 1993-11-02 Ciba-Geigy Corporation Process for stabilizing ethylenically unsaturated compounds and stabilized monomer compositions
TW224983B (https=) * 1991-08-28 1994-06-11 Hoechst Ag
CA2131004A1 (en) * 1992-02-28 1993-09-02 Hideshi Kobayashi S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
HU209678B (en) * 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
IT1263993B (it) * 1993-04-05 1996-09-06 Ciba Geigy Spa Composti piperidin-triazinici atti all'impiego come stabilizzanti per materiali organici
IT1270975B (it) * 1993-06-03 1997-05-26 Ciba Geigy Spa Composti piperidin-triazinici atti all'impiego come stabilizzanti allaluce, al calore e alla ossidazione per materiali organici
DE59505941D1 (de) * 1994-01-19 1999-06-24 Ciba Geigy Ag Stabilisieren von Leder gegen thermische und photochemische Zersetzung
EP0707035B1 (de) * 1994-10-12 1999-01-13 Ciba SC Holding AG HALS-Phosphorinane als Stabilisatoren
EP0711804A3 (de) * 1994-11-14 1999-09-22 Ciba SC Holding AG Kryptolichtschutzmittel
DE19522137A1 (de) * 1995-06-19 1997-01-02 Hoechst Schering Agrevo Gmbh 2-Amino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JP3512911B2 (ja) * 1995-07-11 2004-03-31 富士写真フイルム株式会社 紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法
US6046304A (en) * 1995-12-04 2000-04-04 Ciba Specialty Chemicals Corporation Block oligomers containing 2,2,6,6-tetramethyl-4-piperidyl groups as stabilizers for organic materials
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CN1129597C (zh) * 1997-07-24 2003-12-03 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤剂
JPH11174638A (ja) * 1997-12-08 1999-07-02 Konica Corp ハロゲン化銀カラー写真感光材料
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
US5990208A (en) * 1997-12-15 1999-11-23 Ciba Specialty Chemicals Corporation Stabilization of polycarbonate/ABS blends with mixtures of hindered amines and UV absorbers
WO2000041526A2 (en) * 1999-01-13 2000-07-20 Biomes, Inc. Use of s-triazines for treating apicomplexan parasitic infections
AU775166B2 (en) * 1999-04-22 2004-07-22 H. Lundbeck A/S Selective NPY (Y5) antagonists
MXPA03000504A (es) * 2000-07-19 2003-06-24 Hoffmann La Roche Derivados de pirimidina.
US6465645B1 (en) * 2001-04-17 2002-10-15 Ciba Specialty Chemicals Corporation Long chain hindered amines and compositions stabilized therewith
DE60217322T2 (de) * 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
CA2503451C (en) * 2002-10-25 2011-07-12 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent comprising the same as effective component
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
JP4733021B2 (ja) * 2004-03-31 2011-07-27 全薬工業株式会社 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤
WO2006065872A1 (en) * 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
CA2590586A1 (en) * 2004-12-13 2006-07-06 Neurogen Corporation Substituted biaryl analogues
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
CN101137382B (zh) * 2005-03-11 2012-11-21 全药工业株式会社 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
ZA200802685B (en) * 2005-09-30 2009-10-28 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
TWI498332B (zh) * 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
CN101535296A (zh) * 2006-09-14 2009-09-16 阿斯利康(瑞典)有限公司 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物
JP2010503648A (ja) * 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のためのｐｉ３ｋ及びｍｔｏｒ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−４−（アゼチジン、ピロリジン、ピペリジン、又はアゼピン）ピリミジン誘導体
CN101595103A (zh) * 2006-09-14 2009-12-02 阿斯利康(瑞典)有限公司 嘧啶衍生物
EP2064203A1 (en) * 2006-09-14 2009-06-03 AstraZeneca AB 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008072850A1 (en) * 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
CA2712267A1 (en) * 2008-01-15 2009-07-23 Wyeth Llc 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20090192176A1 (en) * 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521983A (ja) * 2009-03-27 2012-09-20 パトフワイ トヘラペウトイクス インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
US9108980B2 (en) 2009-03-27 2015-08-18 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
JP2013525419A (ja) * 2010-04-30 2013-06-20 ユニバーシティ・オブ・バーゼル 抗増殖性障害の処置における使用のためのｐｉ３ｋ阻害剤としてのピペラジノトリアジン
JP2016516702A (ja) * 2013-03-13 2016-06-09 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法

Also Published As

Publication number Publication date
US20110053907A1 (en) 2011-03-03
WO2009120094A2 (en) 2009-10-01
WO2009120094A3 (en) 2010-01-28
EP2276750A2 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
JP2011515462A (ja) 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
JP5766177B2 (ja) ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
US11787788B2 (en) Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
DK3072890T3 (en) Pyrimidinyl and 1,3,5-triazinylbenzimidazoles and their use in cancer therapy
JP6042406B2 (ja) （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
US10590108B2 (en) Benzimidazoles for use in the treatment of cancer and inflammatory diseases
KR102409739B1 (ko) 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
TW201629019A (zh) ３，５－二胺基吡唑激酶抑制劑
HK1228387B (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
HK1228387A1 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120323

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20120702